For decades, bariatric surgery (BS) has been the most effective treatment for severe obesity, resulting in 2530% WL after the first postoperative year and around 2025% WL long-term [3]
Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions
We believe that there will be a heavy emphasis placed on the marketing department because of the aggressive and non-traditional marketing tactics employed by Novo Nordisk in selling the weight loss drug
The rest of the field, including Lilly's own Zepbound, tops out around 20% to 22% weight loss
The timing of semaglutides effects is a common question among patients at Sanctuary Medical Aesthetic Center in Boca Raton and Fort Lauderdale
Triple-Hormone-Receptor Agonist Retatrutide for Obesity (PubMed abstract)
